申请人:Takeda Pharmaceutical Company Limited
公开号:EP2518054A1
公开(公告)日:2012-10-31
A compound represented by the formula (I)
wherein
ring Cy1 is a 5-membered aromatic heterocycle optionally further substituted besides a group represented by -A-B,
ring Cy2 is an optionally substituted benzene ring,
ring Cy3 is an optionally substituted 5-membered aromatic heterocycle,
ring Cy4 is an optionally substituted 6-membered aromatic ring,
A is -CONRa- or -NRaCO-,
Ra is a hydrogen atom or a substituent,
B is a hydrogen atom or an optionally substituted C1-6 alkyl-group,
X is an optionally substituted C1-2 alkylene, -Y-, -Y-CH2- or - CH2-Y-,
Y is an oxygen atom, -NRb- or -S(O)m-,
Rb is a hydrogen atom or a substituent, and
m is 0, 1 or 2,
provided that
N-methyl-4-[2-[3,4,5-trimethoxyphenyl)amino]-1,3-benzoxazol-7-yl]thiophene-2-carboxamide is excluded,
or a salt thereof,
has an agonistic action on GPR52, and is useful as an agent for the prophylaxis or treatment of schizophrenia and the like.
化合物的化学式为(I),其中环Cy1是一个5-成员芳香杂环,除了由-A-B表示的基团外,还可以进一步取代,环Cy2是一个可选取代的苯环,环Cy3是一个可选取代的5-成员芳香杂环,环Cy4是一个可选取代的6-成员芳香环,A是 -CONRa- 或 -NRaCO-,Ra是氢原子或取代基,B是氢原子或可选取代的C1-6烷基,X是可选取代的C1-2烷基,-Y-,-Y-CH2- 或 - CH2-Y-,Y是氧原子,-NRb- 或 -S(O)m-,Rb是氢原子或取代基,m为0、1或2,提供N-甲基-4-[2-[3,4,5-三甲氧基苯基)氨基]-1,3-苯并噁唑-7-基]噻吩-2-羧酰胺被排除,或其盐,对GPR52有激动作用,并且可用作预防或治疗精神分裂症等疾病的药物。